Petros Pharmaceuticals Releases Pro Forma Financial Statements Highlighting M&A Impact with Vivus Deconsolidation
Petros Pharmaceuticals Inc. has released its unaudited pro forma consolidated balance sheets, shedding light on the financial implications of its recent M&A activities. The statements, dated March 31, 2025, reflect adjustments related to the deconsolidation of subsidiaries and a settlement with Vivus. Notably, the company's common stock saw an increase in issued and outstanding shares to 2,052,762, up from 421,124, as a result of these transactions. Additional paid-in capital rose significantly, reaching approximately $115.99 million, while accumulated deficits were adjusted to $107.99 million. The adjustments also reflect changes in liabilities, with the accounts payable and accrued expenses being notably reduced. These financial statements provide a clearer picture of Petros Pharmaceuticals' financial position following the recent strategic transactions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Petros Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-061230), on June 20, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。